Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Amneal Pharmaceuticals (AMRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$19.45-2.51%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.19 → 1.23 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for AMRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations improves from negative $26.7 million | A primary condition in Amneal Pharmaceuticals's published investment case. The stated target is Cash flow from operations >= $0 million. | Broken | Cash flow remains negative below zero over next 4 quarters | Cash from operations: $-19.262M FY2026-Q2; GAAP. Published target: Cash flow from operations >= $0 million. Target period is not explicitly aligned with this observation. Aug 6, 2026-19,262,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth and strategic expansion story, supported by improving recent financial performance and a biosimilars platform built through the Kashiv acquisition. The long-term thesis is intact, but the business remains loss-making on the earnings-quality measure, and management’s execution record is neutral.
AMRX is tagged as stretched and trades at a 1.48 premium versus peers, with the valuation model pointing to re-rating as a key driver. The expectations gap is 0.13, but the evidence does not explain its scale; valuation therefore appears demanding relative to peers despite low flagged fragility.
Near term, recent results and management delivery are strong: guidance was raised, quarterly revenue increased, and operating income and net income improved. The Kashiv acquisition was completed as planned, though the snapshot gives limited detail on how quickly it will contribute; a guidance reversal would damage credibility, and weakening jobs data could pressure the sector.
Over the multi-year view, the central question is whether the Kashiv platform can broaden growth and whether improved profitability continues. Near term, the thesis is sensitive to management sustaining raised guidance and to sector signals: continued earnings strength from TEVA, HLN, and ZTS would support momentum, while weaker employment data could weigh on cyclical healthcare names.
The 1-to-3-year thesis remains intact, backed by execution and strategic expansion, but stretched valuation and loss-making earnings quality make continued delivery important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful expansion through acquisition of Kashiv BioSciences | The company expands by buying Kashiv BioSciences. | Improving | Acquisition fails or does not contribute to growth by FY26 | Qualitative: Acquisition closed 2026-08-10; FY26 integration target pending Kashiv acquisition closed Aug 2026. Q2 2026 showed record revenue and raised guidance, supporting the M&A growth strategy. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to at least $141.8 million in Q1 2026 | A primary condition in Amneal Pharmaceuticals's published investment case. The stated target is >= $141.8 million. | Intact | Operating income falls below $130 million in Q1 2026 | Operating income: $129.769M FY2026-Q2; GAAP. Published target: >= $141.8 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026129,769,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to at least $3.05 billion in 2026 | Amneal grows revenue about 6% a year to $3.1 billion in 2026. | Intact | Revenue falls below $3.0 billion in FY26 | Revenue: $796.197M FY2026-Q2; GAAP. Published target: >= $3.05 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026796,197,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.12 → $1.23 · observed estimates
$3.33B → $3.49B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-25 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-26 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-27 | $1.12 | $3,335,182,240 | 2 / 3 |
| 2026-07-28 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-29 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-30 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-07-31 | $1.12 | $3,328,722,340 | 5 / 4 |
| 2026-08-01 | $1.16 | $3,356,292,090 | 5 / 4 |
| 2026-08-02 | $1.16 | $3,356,292,090 | 5 / 4 |
| 2026-08-03 | $1.16 | $3,356,292,090 | 5 / 4 |
| 2026-08-04 | $1.16 | $3,356,292,090 | 5 / 4 |
| 2026-08-05 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-06 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-07 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-08 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-09 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-10 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-11 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-12 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-13 | $1.18 | $3,387,738,340 | 5 / 4 |
| 2026-08-14 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-15 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-16 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-17 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-18 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-19 | $1.17 | $3,371,941,907 | 2 / 3 |
| 2026-08-20 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-21 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-22 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-23 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-24 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-25 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-26 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-27 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-28 | $1.18 | $3,387,738,340 | 2 / 3 |
| 2026-08-29 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-08-30 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-08-31 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-01 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-02 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-03 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-04 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-05 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-06 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-07 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-08 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-09 | $1.16 | $3,429,902,683 | 2 / 3 |
| 2026-09-10 | $1.17 | $3,438,582,147 | 2 / 3 |
| 2026-09-11 | $1.17 | $3,438,582,147 | 2 / 3 |
| 2026-09-12 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-13 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-14 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-15 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-16 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-17 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-18 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-19 | $1.17 | $3,438,582,147 | 3 / 3 |
| 2026-09-20 | $1.20 | $3,438,582,147 | 3 / 3 |
| 2026-09-21 | $1.20 | $3,438,582,147 | 3 / 3 |
| 2026-09-22 | $1.20 | $3,438,582,147 | 3 / 3 |
| 2026-09-23 | $1.20 | $3,438,582,147 | 3 / 3 |
| 2026-09-24 | $1.20 | $3,438,582,147 | 3 / 3 |
| 2026-09-25 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-09-26 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-09-27 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-09-28 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-09-29 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-09-30 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-01 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-02 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-03 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-04 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-05 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-06 | $1.19 | $3,444,339,122 | 3 / 4 |
| 2026-10-07 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-08 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-09 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-10 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-11 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-12 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-13 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-14 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-15 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-16 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-17 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-18 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-19 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-20 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-21 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-22 | $1.19 | $3,443,622,455 | 3 / 4 |
| 2026-10-23 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-24 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-25 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-26 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-27 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-28 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-29 | $1.20 | $3,450,911,907 | 3 / 4 |
| 2026-10-30 | $1.21 | $3,457,500,741 | 3 / 4 |
| 2026-10-31 | $1.21 | $3,457,500,741 | 3 / 4 |
| 2026-11-01 | $1.21 | $3,457,500,741 | 3 / 4 |
| 2026-11-02 | $1.21 | $3,457,500,741 | 3 / 4 |
| 2026-11-03 | $1.21 | $3,457,500,741 | 3 / 4 |
| 2026-11-04 | $1.23 | $3,492,813,622 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.